With the deadly COVID-19 which was first originated at the Wuhan province being spread to the many countries one by one, the concerned officials were breaking their shells on how to battle the new virus.
As one such possible was the Queen Mary BioEnterprises Innovation Centre in London is eyeing for 24 volunteers who will volunteer to get injected with the dreaded coronavirus and participate in their flu camp.
Going into details, the experts at the Queen Mary BioEnterprises Innovation Centre, in Whitechapel, London, will infect batches of 24 healthy people with 0C43 and 229E strains of the virus to see if the vaccine works on not.
The volunteers who will be at the Innovation Centre will have to spend two weeks in isolation and eat a restricted diet and they will also not have any physical contact with other people during the study.
The scientists are believing that the new experiment might help in bringing down the outbreak of the Coronavirus which has resulted in deaths of more than 3,500 people worldwide so far.
"Drugs companies can get a very good idea within a few months of starting a vaccine study whether it's working or not, using such a small sample of people," said Andrew Catchpole, Hvivo's chief scientist.
As one such possible was the Queen Mary BioEnterprises Innovation Centre in London is eyeing for 24 volunteers who will volunteer to get injected with the dreaded coronavirus and participate in their flu camp.
Going into details, the experts at the Queen Mary BioEnterprises Innovation Centre, in Whitechapel, London, will infect batches of 24 healthy people with 0C43 and 229E strains of the virus to see if the vaccine works on not.
The volunteers who will be at the Innovation Centre will have to spend two weeks in isolation and eat a restricted diet and they will also not have any physical contact with other people during the study.
The scientists are believing that the new experiment might help in bringing down the outbreak of the Coronavirus which has resulted in deaths of more than 3,500 people worldwide so far.
"Drugs companies can get a very good idea within a few months of starting a vaccine study whether it's working or not, using such a small sample of people," said Andrew Catchpole, Hvivo's chief scientist.